PBM Kickback Prohibition Act
Summary
HR7895 is an early-stage House bill banning referral compensation to PBMs. It has no Senate companion, sits at the start of the legislative process, and has near-zero passage probability in this Congress. Market data shows the three largest PBM-associated stocks (CVS, UNH, CI) have rallied significantly over the past 30 days — this bill is not a driver of those moves. The bill's impact, if enacted, would be immaterial to all three companies' financials.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR7895 is early-stage, low-priority legislation with near-zero passage probability this Congress.
- 2.The bill targets a narrow, non-core PBM revenue stream — referral compensation — not drug pricing or rebates.
- 3.Even if enacted, financial impact on CVS, UNH, and CI would be immaterial relative to total revenues.
- 4.Current market rallies in CVS (+16% 30-day), UNH (+36%), and CI (+10%) are unrelated to this bill.
Market Implications
No material market implication from this bill. CVS at $83.41, UNH at $368.70, and CI at $292.30 have rallied strongly over the past 30 days on earnings and sector dynamics — not on any PBM regulatory shift. This bill is not a catalyst for any of the three tickers. The 52-week ranges show CVS near its high, UNH well off its low but below its high of $411.99, and CI in the middle of its range. Investors should not factor this bill into positions on any of these stocks.
Full Analysis
What happened: On March 12, 2026, Rep. Rick Allen (R-GA) introduced H.R. 7895, the PBM Kickback Prohibition Act. The bill amends ERISA Section 408 to bar pharmacy benefit managers from paying compensation to brokers or advisors for the referral of plan business. The bill was referred to the House Committee on Education and Workforce. As of April 30, 2026, no further action has occurred — no hearings, markup, or Senate companion bill.
The money trail: The bill authorizes $0 in federal spending. It imposes a regulatory prohibition on private sector payment arrangements. No taxpayer funds are involved. No appropriations process is required. The economic effect is purely a removal of a specific private payment stream between PBMs and referral intermediaries.
Structural winners and losers: This bill, if enacted, would theoretically reduce one very narrow cost stream for the three largest PBMs — CVS Caremark, Optum Rx, and Express Scripts. However, referral compensation is a minor, non-core revenue source. None of these companies break out referral fees as a material segment driver. The actual competitive positioning of these PBMs is driven by formulary management, rebate negotiation, and pharmacy network breadth — none of which this bill touches.
Real market data context: Over the past 30 days (March 31 to April 30, 2026), has risen 16.12%, has surged 36.26%, and has gained 9.58%. These moves are driven by earnings, sector rotation, or other market factors — not by this bill. The bill was introduced on March 12 and has generated zero price reaction. At $83.41, is trading near its 52-week high of $85.15. at $368.70 is well above its 52-week low of $234.60. at $292.30 sits roughly in the middle of its 52-week range. The 30-day rallies predate and post-date the bill's introduction without any visible inflection.
Timeline: The bill is at the earliest stage of the legislative process — introduced, referred to committee, no schedule for hearing or markup. With no Senate companion and limited sponsor seniority (Rep. Allen is a junior House Republican), the probability of enactment in the 119th Congress is near zero. Even if it moved, the effective date applies only to plan years beginning after enactment, meaning any real-world impact would be years away.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $598M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $903M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $874M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →